[go: up one dir, main page]

MX2009005909A - Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)eti l]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol. - Google Patents

Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)eti l]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol.

Info

Publication number
MX2009005909A
MX2009005909A MX2009005909A MX2009005909A MX2009005909A MX 2009005909 A MX2009005909 A MX 2009005909A MX 2009005909 A MX2009005909 A MX 2009005909A MX 2009005909 A MX2009005909 A MX 2009005909A MX 2009005909 A MX2009005909 A MX 2009005909A
Authority
MX
Mexico
Prior art keywords
alpha
beta
naphthalenyl
bromo
methoxy
Prior art date
Application number
MX2009005909A
Other languages
English (en)
Inventor
Wim Albert Alex Aelterman
Peter Jozef Maria Van Remoortere
Jean Francois Alexandre Lucas Hegyi
Yolande Lydia Lang
Sigrid Carl Maria Stokbroekx
Carina Leys
Anne Faure
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009005909(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2009005909A publication Critical patent/MX2009005909A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente invención está relacionada con la sal fumarato de (alfa S, beta R)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa -1-naftalenil-beta-fenil-3-quinolinaetanol, composiciones farmacéuticas que comprenden como ingrediente activo dicha sal y con procedimientos para su preparación.
MX2009005909A 2006-12-05 2007-12-03 Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)eti l]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol. MX2009005909A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05
PCT/EP2007/063186 WO2008068231A1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (1)

Publication Number Publication Date
MX2009005909A true MX2009005909A (es) 2009-06-16

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005909A MX2009005909A (es) 2006-12-05 2007-12-03 Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)eti l]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol.

Country Status (34)

Country Link
US (1) US8546428B2 (es)
EP (1) EP2086940B1 (es)
JP (2) JP2010511663A (es)
KR (1) KR101514700B1 (es)
CN (2) CN101547904A (es)
AP (1) AP2498A (es)
AR (1) AR064149A1 (es)
AU (1) AU2007328945B2 (es)
BR (1) BRPI0719693A2 (es)
CA (1) CA2668512C (es)
CL (1) CL2007003472A1 (es)
CY (1) CY1113594T1 (es)
DK (1) DK2086940T3 (es)
EA (1) EA017091B9 (es)
ES (1) ES2387923T3 (es)
HK (1) HK1214513A1 (es)
HR (1) HRP20120639T1 (es)
IL (1) IL199077A (es)
JO (1) JO2973B1 (es)
ME (1) ME01456B (es)
MX (1) MX2009005909A (es)
MY (1) MY148844A (es)
NO (1) NO342773B1 (es)
NZ (1) NZ576485A (es)
PE (1) PE20081350A1 (es)
PL (1) PL2086940T3 (es)
PT (1) PT2086940E (es)
RS (1) RS52408B (es)
SI (1) SI2086940T1 (es)
TW (1) TWI417098B (es)
UA (1) UA97813C2 (es)
UY (1) UY30762A1 (es)
WO (1) WO2008068231A1 (es)
ZA (1) ZA200903907B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
AU2016212116B2 (en) * 2015-01-27 2021-07-15 Janssen Pharmaceutica Nv Dispersible compositions
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
CN108349898B (zh) * 2015-10-20 2021-03-23 浙江海正药业股份有限公司 富马酸贝达喹啉的晶型及其制备方法
PT3971177T (pt) * 2016-07-20 2024-07-30 Novartis Ag Derivados de aminopiridina e a sua utilização como inibidores seletivos de alk-2
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
EP3651736B1 (en) 2017-07-14 2021-06-23 Janssen Pharmaceutica NV Long-acting formulations
US20220023282A1 (en) * 2018-12-13 2022-01-27 Mannkind Corporation Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
US20220062319A1 (en) 2019-01-09 2022-03-03 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
US20230346770A1 (en) 2020-11-12 2023-11-02 Janssen Pharmaceutica Nv Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) * 2022-07-07 2025-06-24 上海交通大学 含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
JP2001503411A (ja) * 1996-10-28 2001-03-13 ディパートメント オブ ジ アーミー，ユー．エス．ガバメント 抗生物質耐性感染症の処置のための化合物、組成物および方法
IL122026A0 (en) * 1996-10-30 1998-03-10 Lilly Co Eli Improvements in or relating to the prophylaxis of breast cancer
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
RS52431B (sr) 2002-07-25 2013-02-28 Janssen Pharmaceutica N.V. Derivati hinolina i njihova upotreba kao mikobakterijskih inhibitora
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
ES2306146T3 (es) * 2004-05-28 2008-11-01 Janssen Pharmaceutica Nv Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a farmacos.
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
EA009779B1 (ru) * 2004-12-24 2008-04-28 Янссен Фармацевтика Н.В. Лечение латентного туберкулёза

Also Published As

Publication number Publication date
RS52408B (sr) 2013-02-28
CA2668512A1 (en) 2008-06-12
ZA200903907B (en) 2013-08-28
CN101547904A (zh) 2009-09-30
HRP20120639T1 (hr) 2012-08-31
AR064149A1 (es) 2009-03-18
JO2973B1 (en) 2016-03-15
ES2387923T3 (es) 2012-10-04
HK1214513A1 (zh) 2016-07-29
NO20092535L (no) 2009-08-06
US8546428B2 (en) 2013-10-01
CN105012303A (zh) 2015-11-04
US20100028428A1 (en) 2010-02-04
IL199077A (en) 2016-09-29
CY1113594T1 (el) 2016-06-22
CA2668512C (en) 2015-03-24
PL2086940T3 (pl) 2012-10-31
NZ576485A (en) 2012-01-12
EA200970532A1 (ru) 2009-10-30
MY148844A (en) 2013-06-14
PT2086940E (pt) 2012-08-09
KR101514700B1 (ko) 2015-04-24
CL2007003472A1 (es) 2008-08-22
TWI417098B (zh) 2013-12-01
AP2498A (en) 2012-10-19
SI2086940T1 (sl) 2012-09-28
EA017091B1 (ru) 2012-09-28
PE20081350A1 (es) 2008-09-18
EP2086940A1 (en) 2009-08-12
AU2007328945B2 (en) 2014-04-03
ME01456B (me) 2014-04-20
TW200838527A (en) 2008-10-01
KR20090087020A (ko) 2009-08-14
BRPI0719693A2 (pt) 2013-12-24
JP2010511663A (ja) 2010-04-15
DK2086940T3 (da) 2012-08-20
EP2086940B1 (en) 2012-05-16
UA97813C2 (uk) 2012-03-26
AP2009004870A0 (en) 2009-06-30
JP5894239B2 (ja) 2016-03-23
AU2007328945A1 (en) 2008-06-12
UY30762A1 (es) 2008-07-03
EA017091B9 (ru) 2014-10-30
WO2008068231A1 (en) 2008-06-12
NO342773B1 (no) 2018-08-06
JP2015028049A (ja) 2015-02-12

Similar Documents

Publication Publication Date Title
MX2009005909A (es) Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)eti l]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol.
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
CL2008000946A1 (es) Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun
MX2009011276A (es) Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad.
IL193357A0 (en) Metoprolol succinate e.r. tablets and methods for their preparation
MX2010002210A (es) Derivados de catecolamina y profarmacos de los mismos.
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MY164864A (en) Indenone derivative and pharmaceutical composition comprising same
TW200738653A (en) Anthranilamide/2-amino-heteroarene carboxamide derivatives
TW200745122A (en) New compounds I
WO2010061220A3 (en) Novel processes and pure polymorphs
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
TW200745133A (en) New compounds II
HU0700433D0 (en) Compounds influencing development or functioning of cellular vesicular systems particularly lipid droplets, pharmaceutical compositions containing these compounds and use them for treatment of illnesses
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
UA93864C2 (ru) Соединения нафталина, способ их получения и фармацевтическая композиция, которая содержит их
WO2010061219A3 (en) Polymorphs
ZA200800414B (en) Crystalline forms of macrolide compounds endowed with antiinflammatory activity
TW200736270A (en) Macrolones
TN2010000431A1 (en) New formulations, tablets comprising such formulations, their use and process for their preparation
CU23678B7 (es) Procedimiento de preparación de la forma cristalina delta del clorhidrato de la ivabradina y las composiciones farmacéuticas que lo contienen

Legal Events

Date Code Title Description
FG Grant or registration